Abcam, ab258293, Human ABHD6 knockout HeLa cell lysate

Size: 1Kit
ABHD6 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon5 and 2 bp deletion in exon5 and 5 bp deletion in exon5.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon5 and 2 bp deletion in exon5 and 5 bp deletion in exon5.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ABHD6, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ABHD6 also known as Alpha/Beta-Hydrolase Domain-Containing Protein 6 is a serine hydrolase enzyme with a molecular weight of around 40 kDa. This protein is expressed predominantly in the brain with presence also in other tissues such as the liver lungs and immune cells. Mechanically ABHD6 functions by hydrolyzing the lipid monoacylglycerol particularly 2-arachidonoylglycerol (2-AG) which is an endocannabinoid. By doing this ABHD6 plays a critical role in regulating lipid signaling pathways.
Biological function summary
ABHD6 affects endocannabinoid signaling by breaking down 2-AG into arachidonic acid and glycerol. This process positions ABHD6 as an essential regulator of cellular lipid balance and signaling. It is not typically part of a larger complex; ABHD6 operates mainly as a single enzyme. However its interaction with lipids impacts diverse cellular mechanisms including those related to metabolism and neural activity.
Pathways
The enzyme significantly affects the endocannabinoid and lipid metabolism pathways. ABHD6 is involved in modulating the levels of 2-AG influencing neurotransmission and inflammation. It sits within the same metabolic framework as other enzymes like monoacylglycerol lipase (MAGL) and diacylglycerol lipase both of which are important in the lipid signaling pathway. These interactions emphasize the role of ABHD6 in maintaining cellular homeostasis and influencing various physiological processes through lipid metabolism.
ABHD6 is associated with neurological disorders such as epilepsy and Alzheimer's disease. Alterations in ABHD6 expression or activity can lead to dysregulated endocannabinoid signaling which influences the severity and progression of these conditions. Furthermore ABHD6 is connected to neuroinflammation alongside proteins such as COX-2 which also participates in the inflammatory response. The understanding of ABHD6's role in these diseases could open new therapeutic avenues targeting lipid signaling pathways.